Hiroko Yamashita1, Akiko Ogiya2, Tadahiko Shien3, Yoshiya Horimoto4, Norikazu Masuda5, Touko Inao6, Tomofumi Osako7,8, Masato Takahashi9, Yumi Endo10, Mitsuchika Hosoda11, Naoko Ishida11, Rie Horii12, Kieko Yamazaki2, Yuichiro Miyoshi3, Hiroyuki Yasojima5, Nobumoto Tomioka9. 1. Breast Surgery, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. hirokoy@huhp.hokudai.ac.jp. 2. Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. 3. Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. 4. Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan. 5. Department of Surgery, Breast oncology, NHO Osaka National Hospital, Osaka, Japan. 6. Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan. 7. Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan. 8. Kumamoto Shinto General Hospital, Kumamoto, Japan. 9. Department of Breast Surgery, NHO Hokkaido Cancer Center, Sapporo, Japan. 10. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 11. Breast Surgery, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan. 12. Division of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Abstract
BACKGROUND: Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer. METHODS: A total of 223 patients (108 premenopausal and 115 postmenopausal) with early distant recurrence and 149 patients (62 premenopausal and 87 postmenopausal) with late distant recurrence of ER-positive, HER2-negative breast cancer who were given their initial treatment between 2000 and 2004 were registered from nine institutions. For each late recurrence patient, approximately two matched control patients without relapse for more than 10 years were selected. Clinicopathological factors and adjuvant therapies were compared among the three groups by menopausal status and age. RESULTS: Factors predicting early recurrence in premenopausal women were large tumor size, high lymph node category and high tumor grade, whereas predictors for late recurrence were large tumor size and high lymph node category. In postmenopausal women under 60 years of age, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, low PgR expression and high Ki67 labeling index (LI), while predictors for late recurrence were large tumor size and high lymph node category. On the other hand, in postmenopausal women aged 60 years or older, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, high tumor grade, low ER expression and high Ki67 LI, whereas predictors for late recurrence were high lymph node category, low ER expression and short duration of adjuvant endocrine therapy. CONCLUSION: Predictors of early and late distant recurrence might differ according to menopausal status and age.
BACKGROUND: Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer. METHODS: A total of 223 patients (108 premenopausal and 115 postmenopausal) with early distant recurrence and 149 patients (62 premenopausal and 87 postmenopausal) with late distant recurrence of ER-positive, HER2-negative breast cancer who were given their initial treatment between 2000 and 2004 were registered from nine institutions. For each late recurrence patient, approximately two matched control patients without relapse for more than 10 years were selected. Clinicopathological factors and adjuvant therapies were compared among the three groups by menopausal status and age. RESULTS: Factors predicting early recurrence in premenopausal women were large tumor size, high lymph node category and high tumor grade, whereas predictors for late recurrence were large tumor size and high lymph node category. In postmenopausal women under 60 years of age, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, low PgR expression and high Ki67 labeling index (LI), while predictors for late recurrence were large tumor size and high lymph node category. On the other hand, in postmenopausal women aged 60 years or older, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, high tumor grade, low ER expression and high Ki67 LI, whereas predictors for late recurrence were high lymph node category, low ER expression and short duration of adjuvant endocrine therapy. CONCLUSION: Predictors of early and late distant recurrence might differ according to menopausal status and age.
Entities:
Keywords:
Breast cancer; Early recurrence; Estrogen receptor positive; HER2 negative; Late recurrence
Authors: Claire Buchta Rosean; Raegan R Bostic; Joshua C M Ferey; Tzu-Yu Feng; Francesca N Azar; Kenneth S Tung; Mikhail G Dozmorov; Ekaterina Smirnova; Paula D Bos; Melanie R Rutkowski Journal: Cancer Res Date: 2019-05-07 Impact factor: 12.701
Authors: Soo Yeon Baek; Ji Yeong Kwon; Young Joo Lee; Sung-Chan Gwark; Sae Byul Lee; Jisun Kim; Il Yong Chung; Beom Seok Ko; Hee Jeong Kim; Sung-Bae Kim; Seung Do Ahn; Gyungyub Gong; Byung Ho Son; Sei-Hyun Ahn; Jong Won Lee Journal: J Breast Cancer Date: 2019-08-01 Impact factor: 3.588